Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | LSS | P48449 | 2/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500340 | 0.89 | TSHR (0.46) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8763412 | 0.84 | LMNA (0.50) | CA12CA1CA2CA4MAPT | |
| SCHEMBL7234638 | 0.82 | CA12 (0.58) | CA12CA1CA2CA4CA9 | |
| SCHEMBL517816 | 0.81 | LOXL2 (0.59) | CA12CA1CA2CA4CA9 | |
| SCHEMBL2246626 | 0.79 | KCNJ1 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8763272 | 0.78 | LMNA (0.46) | CA12CA1CA2CA4TSHR | |
| SCHEMBL1983770 | 0.76 | LOXL2 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4864848 | 0.76 | TSHR (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL26148107 | 0.76 | CYP2A6 (0.55) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6562364 | 0.76 | KCNJ1 (0.50) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-1085009-B1 | INDAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-0934296-B1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6486178-B1 | Indane derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1085009-A1 | INDAN DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | CA12 2954/4885CA1 3214/4885CA2 1250/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | CA12 2780/4885CA1 3024/4885CA2 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.